Inca Minerals (ICG:AU) has announced Stunalara Acceptances Reach 54%
Download the PDF here.
This post appeared first on investingnews.com
Silver47 Exploration Corp. (TSXV: AGA) (‘Silver47’ or the ‘Company’) is pleased to announce the closing of an additional tranche (the ‘Additional Tranche’) of its previously announced non-brokered private placement (the ‘Private Placement’) (as set out in the Company’s news releases dated February 19 and 24, 2025). Pursuant to the closing of the Additional Tranche, the Company issued 4,155,000 units of the Company (the ‘Units’) at a price of $0.50 each for aggregate gross proceeds to the Company of $2,077,500. The Company anticipates completing the balance of the Private Placement on or around March 19, 2025 or as may be determined by the Company.
Each Unit consists of one common share in the capital of the Company (a ‘Common Share‘) and one-half of one Common Share purchase warrant (a ‘Half-Warrant‘, with two Half-Warrants being referred to as a ‘Warrant‘). Each Warrant entitles the holder thereof to acquire one Common Share at a price of $0.75 within 36 months following issuance. The Company intends to use the net proceeds from the sale of the Units to fund exploration activities at the Red Mountain Project in Alaska and for general working capital.
In connection with the Additional Tranche, the Company paid certain persons (‘Finders‘) finders’ fees totaling $10,220 in cash, representing 7% of the aggregate proceeds raised by the Finders, and issued 20,440 finders’ warrants (the ‘Finder’s Warrants‘), representing 7% of the number of securities sold to subscribers introduced to the Company by the Finders. Each Finder’s Warrant is exercisable for one Common Share at an exercise price of $0.75 for a period of 36 months from the date of issuance.
All securities issued under the Private Placement are subject to a hold period of four months and one day from the date of issuance under applicable securities laws. The Private Placement is subject to the final approval of the TSX Venture Exchange (the ‘TSXV‘) to be obtained on completion of the Private Placement.
This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the ‘1933 Act‘), or any state securities laws and may not be offered or sold in the ‘United States’ or to ‘U.S. persons’ (as such terms are defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available.
About Silver47 Exploration Corp.
Silver47 wholly-owns three silver and critical metals (polymetallic) exploration projects in Canada and the US: the Flagship Red Mountain silver-gold-zinc-copper-lead-antimony-gallium VMS-SEDEX project in southcentral Alaska; the Adams Plateau silver-zinc-copper-gold-lead SEDEX-VMS project in southern British Columbia, and the Michelle silver-lead-zinc-gallium-antimony MVT-SEDEX Project in Yukon Territory. Silver47 Exploration Corp. shares trade on the TSXV under the ticker symbol AGA. For more information about Silver47, please visit our website at www.silver47.ca.
On Behalf of the Board of Directors
Mr. Gary R. Thompson
Director and CEO
gthompson@silver47.ca
For investor relations
Meredith Eades
info@silver47.ca
778.835.2547
No securities regulatory authority has either approved or disapproved of the contents of this release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
FORWARD-LOOKING STATEMENTS
This release contains certain ‘forward looking statements’ and certain ‘forward-looking information’ as defined under applicable Canadian securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as ‘may’, ‘will’, ‘expect’, ‘intend’, ‘estimate’, ‘upon’ ‘anticipate’, ‘believe’, ‘continue’, ‘plans’ or similar terminology. Forward-looking statements and information include, but are not limited to: closing of the Private Placement, including the number of Units and FT Units issued in respect thereof; anticipated use of proceeds; expected closing date of the Private Placement; payment of finder’s fees; ability to obtain all necessary regulatory approvals; insider participation in the Private Placement; the statements in regards to existing and future products of the Company; and the Company’s plans and strategies. Forward-looking statements and information are based on forecasts of future results, estimates of amounts not yet determinable and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause the Company’s actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein, including but not limited to: the ability to close the Private Placement, including the time and sizing thereof, the insider participation in the Private Placement and receipt of required regulatory approvals; the use of proceeds not being as anticipated; the Company’s ability to implement its business strategies; risks associated with general economic conditions; adverse industry events; stakeholder engagement; marketing and transportation costs; loss of markets; volatility of commodity prices; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; industry and government regulation; changes in legislation, income tax and regulatory matters; competition; currency and interest rate fluctuations; and the additional risks identified in the Company’s financial statements and the accompanying management’s discussion and analysis and other public disclosures recently filed under its issuer profile on SEDAR+ and other reports and filings with the TSXV and applicable Canadian securities regulators. The forward-looking information are made based on management’s beliefs, estimates and opinions on the date that statements are made and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws.
No forward-looking statement can be guaranteed, and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISTRIBUTION OR DISSEMINATION IN OR INTO THE U.S.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/244400
News Provided by Newsfile via QuoteMedia
This post appeared first on investingnews.com
President Donald Trump’s economic policies and vision for US trade have reignited speculation about a potential multinational deal aimed at addressing what some view as a persistently overvalued dollar.
Although no formal agreement has been announced, analysts have coined the term “Mar-a-Lago Accord” to describe a possible effort to rebalance global currency markets, borrowing from the 1985 Plaza Accord.
Origins of the ‘Mar-a-Lago Accord’
The phrase has gained traction following a paper written in November 2024 by Stephen Miran, Trump’s nominee for the White House Council of Economic Advisers. In it, Miran proposed several strategies to reform global trade and counteract the economic imbalances caused by what he called an excessively strong dollar.
Similarly, incoming Treasury Secretary Scott Bessent suggested in June 2024 that a “grand economic reordering” could take place in the coming years.
While details remain speculative, the general premise behind the Mar-a-Lago Accord revolves around Trump’s commitment to boosting American manufacturing and exports.
The challenge, however, lies in the dollar’s current strength, which makes US goods less competitive abroad. With the US trade deficit reaching a record US$1.2 trillion in 2024, some economists argue that a weaker dollar could help bridge the gap by making American exports more attractive.
The idea of a coordinated effort to weaken the dollar is not new. In 1985, the US and key trading partners—including Japan, France, the UK, and West Germany—agreed to the Plaza Accord, a deal aimed at curbing the dollar’s strength.
At the time, US manufacturers were struggling against Japan’s export dominance, much like today’s concerns regarding China.
The Plaza Accord succeeded in lowering the dollar’s value, but it also had unintended consequences, such as Japan’s economic stagnation in the 1990s.
Potential mechanisms of a Mar-a-Lago Accord
If such an agreement were to take shape, it could involve several key components. Trade and tariff adjustments could be central, as Trump has floated the idea of replacing the Internal Revenue Service with an “External Revenue Service” that collects funds from foreign countries, indicating a shift toward economic policies that could pressure trading partners into compliance.
Currency interventions might also play a role, with governments potentially agreeing to coordinated efforts in foreign-exchange markets to adjust currency values.
However, given today’s massive US$7.5 trillion daily forex trading volume, direct interventions might be less effective than they were in the 1980s.
Adrian Day, president of Adrian Day Asset Management, notes that these ideas form a “loose collection of disparate policies” rather than a cohesive plan.
He also emphasized that Trump often starts negotiations with extreme positions before settling on more moderate policies.
A significant aspect of this discussion revolves around security. The US has long subsidized defense for Europe and other allies, and Trump has suggested that foreign governments should bear a larger financial burden.
Debt restructuring is another controversial idea. “The US will require foreign governments who hold Treasuries to exchange those Treasuries for 100-year non-tradable zero coupons,” Day noted, adding that the proposal ties these exchanges to security commitments, using military presence as leverage.
“Carrot and stick—we’ll keep the Seventh Fleet in the Red Sea if you exchange your Treasuries, but if you don’t, you’re on your own.”
A weaker dollar could lead to higher inflation by increasing the cost of imports. Investors who traditionally see US assets as a safe haven might also shift capital toward alternative currencies such as the euro or yen.
Furthermore, any attempt to force trading partners into an unfavorable debt swap could disrupt the US$29 trillion Treasury market, a cornerstone of global finance.
What It means for gold
One of the most consistent takeaways from discussions around the Mar-a-Lago Accord is its bullish implications for gold.
A weaker dollar historically drives demand for gold as a store of value, and uncertainty surrounding U.S. debt policies could further boost the metal’s appeal. “Every single one of these proposals is gold bullish,” Day remarked.
An additional subject of market speculation is the idea that the administration could try to make use of the country’s gold stockpile. At current market prices, the gold held in Fort Knox, Kentucky, and other locations would be worth about US$758 billion, but it is valued at only US$11 billion on the Federal Reserve’s balance sheet due to a 1973 law that set its price.
Trump and Elon Musk have both expressed interest in verifying that the gold reserves remain intact, fueling further speculation.
Meanwhile, Bessent has discussed the potential of monetizing “the asset side of the US balance sheet for the American people,” though he has clarified that a gold revaluation is not what he had in mind.
Analysts speculate that any push to devalue the dollar while restructuring US obligations could set off a chain reaction in commodities markets, further amplifying gold’s importance.
If foreign investors perceive US economic policies as a shift away from traditional fiscal discipline, they may increase their allocations to gold as a hedge against potential volatility in Treasury markets.
While the Mar-a-Lago Accord remains more of a concept than a concrete policy, its potential implications are vast. The coming months will reveal whether the Trump administration formally pursues these strategies or if they remain theoretical discussions among economists and strategists.
Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.
This post appeared first on investingnews.com
Life science companies developing bird flu vaccines are gaining attention as the avian influenza subtype H5N1 becomes an increasing concern.
The United States is in the midst of an H5N1 bird flu outbreak that began in February 2024 and is now threatening the nation’s poultry and cattle industries. With poultry farmers across the US needing to cull their flocks if the virus is detected to prevent it spread, egg prices are shocking shoppers at the country’s grocery stores. Highly pathogenic avian influenza (HPAI) has also spread to cattle and other mammals, including cats.
Human avian influenza cases have so far been rare during this outbreak in the US, as currently the virus is only spread to humans through exposure to infected animals. As of February 27, 2025, 67 human cases have been detected in the country, and one death has been reported. However, concerns such as the possibility of mutations that could increase the chance of human-to-human transmission are stoking calls for better preparedness and access to bird flu vaccines.
In this article:
Is there a vaccine for bird flu?
There are several bird flu vaccines approved for treating avian influenza in humans, with others under development.
The Center for Disease Control and Prevention (CDC), a US federal agency under the Department of Health and Human Services, currently holds three different US Food and Drug Administration (FDA) approved vaccines in its strategic national stockpile that can be rapidly updated to address the current strain.
In the United States, the vaccines would be reserved for workers in the poultry industry if human cases escalate and could be scaled up further if needed in the case of a bird flu pandemic in humans.
Health Canada has authorized two H5N1 vaccines and laid out a framework for deciding whether to use the vaccines in a non-pandemic context, including increased human cases, human-to-human transmission and increasing severity of outcomes.
Which companies are producing vaccines for bird flu?
Some of the biggest companies in the pharmaceutical industry are either producing vaccines for bird flu or actively developing new drug candidates to fight the virus. There are also a number of large-cap and small-cap life science companies with avian influenza vaccines under development.
Below are eight bird flu vaccine stocks for investor consideration and details of their work on avian influenza. The stocks are listed by market cap based on figures retrieved from TradingView’s stock screener on March 12, 2025.
1. Sanofi (NASDAQ:SNY)
Company Profile
Market cap: US$148.84 billion
Sanofi develops therapeutic products for diabetes and cardiovascular diseases, oncology, immunology, multiple sclerosis, rare diseases, and rare blood disorders. The French multinational pharmaceutical company is also one of the world’s largest manufacturers of vaccines.
Sanofi’s H5N1 vaccine became the first to be approved by the US FDA back in 2007. Today, it is one of only three US FDA-approved H5N1 vaccines held in the US national stockpile, joined by vaccines from two other pharma firms on this list, CSL Seqirus and GSK.
In October 2024, the three pharma companies were awarded a combined US$72 million by the US Administration for Strategic Preparedness and Response. The companies will prepare doses of their vaccines to be available if needed, and ‘manufacture additional bulk influenza antigen … from seed stocks that are well matched to circulating strains.’
2. Pfizer (NYSE:PFE)
Company Profile
Market cap: US$147.29 billion
Pfizer is a world-renowned research pharmaceutical company developing drugs in a wide range of areas, including oncology, inflammation and immunology, vaccines, internal medicine and rare diseases. Pfizer and BioNTech created the first FDA-approved mRNA-based COVID-19 vaccine in 2020.
Pfizer’s mRNA technology could be targeted at producing an avian flu vaccine. In a May 2024 press release, the company stated that it is prepared to address an H5 group influenza pandemic, and reported that in late 2023 it had ‘initiated a randomized Phase 1 study to evaluate the safety, tolerability, and immunogenicity of multiple doses of nucleoside-modified mRNA (modRNA) based pandemic influenza vaccine candidate.’
3. GSK (NYSE:GSK)
Company Profile
Market cap: US$81.76 billion
British multinational biotech company GSK has three main business divisions: pharmaceuticals, consumer healthcare and vaccines. Its vaccine Arexvy is the world’s first respiratory syncytial virus (RSV) vaccine for older adults and is approved for ages 50 and up.
GSK subsidiary ID Biomedical Corporation of Quebec produces Arepanrix, an H5N1 virus monovalent vaccine, is among the three avian flu vaccines in the US stockpile.
“GSK’s H5N1 pandemic vaccine can generate some cross-neutralizing antibodies against the current circulating strains and is recognized as an important tool in reducing illness during a possible H5N1 pandemic,” a GSK spokesperson told PharmaVoice. “The vaccine is designed to be updated with the latest circulating strain of interest, as identified by the WHO.”
In February 2025, the Public Health Agency of Canada announced that through an existing deal with GSK, it has secured an initial supply of 500,000 doses of its avian influenza vaccine.
GSK also has a mRNA-based H5N1 pre-pandemic vaccine in Phase 2 studies for adults 18 and older. GSK’s mRNA candidate vaccines were previously being developed in partnership with German biopharma CureVac, another company on this list. However, the two restructured the partnership in July 2024, and GSK now has full rights to development, manufacturing and commercialization.
4. CSL (ASX:CSL,OTCQX:CMXHF)
Company Profile
Market cap: US$75.51 billion
Australian multinational biotechnology firm CSL is the parent company of CSL Seqirus, one of the world’s largest influenza vaccine makers. CSL Seqirus has production facilities in the United States, the United Kingdom and Australia.
CSL Seqirus’ Audenz is among the three avian flu vaccines that make up US stockpiles. The company describes Audenz, which the FDA approved in 2020, as ‘the first-ever adjuvanted, cell-based influenza vaccine designed to protect against influenza A (H5N1) in the event of a pandemic.’
CSL Seqirus has a manufacturing facility in North Carolina that was built through a public-private partnership with the US government in 2009. According to the company, the facility is the world’s largest cell-based influenza vaccine producer and its highly scalable production method means it’s capable of delivering 150 million influenza vaccine doses within a six-month timeframe as part of an influenza pandemic response.
5. Moderna (NASDAQ:MRNA)
Company Profile
Market cap: US$13.03 billion
Moderna leads the world in the field of mRNA-based medicine from immuno-oncology to infectious diseases, as best demonstrated by its rapid deployment of effective COVID-19 vaccines. The company’s integrated manufacturing plant allows for both clinical and commercial production.
Moderna’s mRNA-based bird flu vaccine mRNA-1018 is undergoing a Phase 1/2 study targeting H5 and H7 avian influenza viruses.
In January 2025, the US Department of Health and Human Services (HHS) under the Biden Administration stated it would award Moderna US$590 million to “accelerate the development of mRNA-based pandemic influenza vaccines and enhance mRNA platform capabilities so that the U.S. is better prepared to respond to other emerging infectious diseases.” This includes its investigational avian flu vaccine.
Bloomberg reported in late February that funding is now in question as Robert F. Kennedy Jr., a long-time anti-vaccine activist, has taken the reins of the HHS under the Trump administration. Republican lawmakers in several states are also putting forth legislation to ban mRNA vaccines.
6. Novavax (NASDAQ:NVAX)
Company Profile
Market cap: US$1.27 billion
American vaccine developer Novavax has a pipeline of early and late-stage vaccine candidates targeting respiratory viruses and other serious infectious diseases. The biotech’s platform is based on its proprietary recombinant protein-based nanoparticle and Matrix-M adjuvant technology.
Sanofi signed a US$1.2 billion co-exclusive license in May 2024 to co-commercialize Novavax’s adjuvanted COVID-19 vaccine through much of the world.
Novavax is also conducting pre-clinical studies on a vaccine for H5N1 avian pandemic influenza using its novel approach to immunization. According to the company, ‘Non-human primate studies have shown (its) vaccine candidate can produce protective levels of immunity after a single dose.’
7. CureVac (NASDAQ:CVAC)
Company Profile
Market cap: US$708.81 million
CureVac is a pioneer in developing mRNA medicines, and the first biotech company in the world “to successfully harness mRNA for medical purposes,” according to its company website. The company’s mRNA-based pipeline is based its on its proprietary RNA technology platform. It focuses on three therapeutic areas: prophylactic vaccines, cancer immunotherapies and molecular therapies.
CureVac also has an in-house GMP manufacturing facility capable of large-scale production of vaccine doses.
In 2024, CureVac, in partnership with GSK, began a Phase 1/2 study in the United States on an investigational mRNA-based bird flu vaccine for healthy younger adults aged 18 to 64 and healthy older adults aged 65 to 85 years of age. The vaccine candidate has since been fully licensed to GSK.
8. Arcturus Therapeutics (NASDAQ:ARCT)
Company Profile
Market cap: US$358.25 million
California-based Arcturus Therapeutics is a global commercial mRNA medicines and vaccines company. Its pipeline is focused on the development of infectious respiratory disease vaccines.
Arcturus is developing an avian flu vaccine based on its STARR self-amplifying mRNA vaccine platform technology. In 2022, the company was awarded US$63.2 million by the US HHS to support development of this vaccine for rapid pandemic influenza response. Phase 1 clinical trials for its H5N1 vaccine candidate began in January and is fully funded by the Biomedical Advanced Research and Development Authority, part of the US HHS.
Antiviral influenza stocks
Life science stocks with commercial or clinical-stage antiviral influenza medications are also worth considering for investors interested in bird flu stocks. Here are a few to get you started, listed in alphabetical order.
CoCrystal Pharma (NASDAQ:COCP)
CoCrystal Pharma is a clinical-stage biotech company with a focus on developing antiviral treatments, specifically for influenza, norovirus and COVID-19. The company’s oral influenza PB2 inhibitor CC-42344 is targeted at pandemic and seasonal influenza. Currently in Phase 2a studies, the treatment has shown in vitro activity against the avian influenza A PB2 protein.
NanoViricides (NYSEAMERICAN:NNVC)
NanoViricides is a clinical stage nanomedicine technology company. Its lead drug candidate is NV-387, a broad spectrum antiviral therapy that works by mimicking a host-side signature that viruses respond to, meaning it should be effective even as viruses mutate over time. NV-837 is developed to treat respiratory viral infections such as RSV, COVID, Long COVID, and H5N1 as well as Mpox, smallpox and measles infections. The company has successfully completed Phase 1 studies.
Roche (OTCQX:RHHBY,SWX:RO)
Switzerland-headquartered F. Hoffmann-La Roche, commonly known as Roche, is one of the world’s largest pharmaceutical companies by revenue. Along with hematology, oncology, neuroscience, and women’s health, the company also targets infectious diseases. Its drug Tamiflu is one of the leading seasonal influenza antiviral treatments, and it can be used to treat avian flu as well.
Traws Pharma (NASDAQ:TRAW)
Traws Pharma is a clinical stage company leveraging its expertise in small molecule chemistry, artificial intelligence and machine learning in the efficient development of medicines addressing respiratory viral diseases. The company’s single-dose H5N1 bird flu antiviral, tivoxavir marboxil, is entering Phase 2 studies in the first half of 2025.
FAQs for bird flu vaccines
Is there a bird flu vaccine for chickens?
There are bird flu vaccines for chickens, and farmers in nations such as China, France, Egypt and Mexico use them to inoculate their flocks.
However, the avian flu vaccines for birds are not commonly used in the United States as they pose logistical challenges and create barriers to trade. In terms of trade, some US trading partners won’t purchase vaccinated chickens as the vaccine can mask an avian flu infection.
Instead, biosecurity measures such as sanitation and protective wear for workers, and culling of infected flocks are more common practices in the United States.
In response to the current bird flu outbreak, in mid-February 2025, the US Department of Agriculture conditionally approved a bird flu vaccine for chickens made by Zoetis (NYSE:ZTS), the world’s largest producer of medicine and vaccinations for pets and livestock.
Is there a bird flu vaccine for cattle?
There are bird flu vaccines for cattle under development. For example, Medgene, a privately held animal health company based in South Dakota, is developing an H5N1 vaccine for cattle that as of late February 2025 is waiting on imminent conditional approval from the US Department of Agriculture. The company has signed a distribution agreement with global animal health company Elanco Animal Health (NYSE:ELAN) for the vaccine.
Is there a bird flu vaccine for cats and dogs?
While both animals can catch avian flu, there are no commercial bird flu vaccines are currently available for cats and dogs. Cats are at higher risk of contracting HPAI bird flu than dogs, but owners of both should take precautionary measures.
The American Veterinary Medical Association advises cats should be kept indoors. Pet owners should keep outdoor pets, including backyard chicken flocks, away from the wild birds, poultry and cattle.
Additionally, pet owners must avoid feeding pets raw meat or poultry and unpasteurized milk, and prevent pets from eating dead birds or other animals.
Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.
This post appeared first on investingnews.com
John Feneck, portfolio manager and consultant at Feneck Consulting, shares his updated outlook for gold, saying that the yellow metal still has space to run.
He also discusses nine gold and ‘special situations’ companies that are on his radar.
Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.
This post appeared first on investingnews.com
Brian Leni, founder of Junior Stock Review, runs through his investment strategy, saying he’s looking for stocks with an ‘X factor’ that’s being overlooked.
Watch the interview above for more of this thoughts.
Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.
This post appeared first on investingnews.com
Platinum moved into a more pronounced deficit position in 2024, with demand outstripping supply of the precious metal by nearly 1 million ounces, according to the World Platinum Investment Council’s (WPIC) Platinum Quarterly for Q4 2024.
A significant portion of that came in the final quarter of the year, when the deficit grew by 313,000 ounces.
This was driven largely by investment demand on the back of Donald Trump’s victory in the presidential election and subsequent rhetoric over planned trade and foreign policy.
Increased demand adding to supply draw down
According to the new report, the platinum deficit deepened in Q4 on the back of weaker recycling supply and stronger investment demand, coming in 313,000 ounces deeper than the council forecasted in its Q3 2024 report released in November.
In total, the last quarter of 2024 saw 360,000 ounces of demand uptake from investor inflows into the platinum market. On a more granular level, this demand came from 92,000 ounces of platinum bar and coin purchases, 142,000 ounces in platinum inflows to exchange traded funds (ETFs) and 126,000 ounces of platinum moving into exchange stocks. The WPIC defines exchange stocks as ‘platinum ounces held in approved storage facilities that serve as collateral for futures positioning.’
“So back in December, when the incoming Trump administration started talking about the threat of tariffs, we began to see that impact on the commodity markets in terms of distorting the flow of metals versus what would happen normally,” he said.
Similar to what was reported in gold markets, this resulted in institutional players moving physical products from Europe into New York Mercantile Exchange-approved warehouses in the United States.
“They needed to get that into the States because they’ve suddenly begun to worry that they might have to pay tariffs when they bring that material in in the future, and that would obviously impinge on profitability,” Sterck said.
Watch the full interview with Sterck above.
In its projection for 2025, Sterck said the council sees a continuation of trends from 2024 and is predicting a third year of platinum deficits with an 848,000 ounce shortfall.
In its initial assessment, the WPIC expected 150,000 ounces of full year demand to come from exchange inflows to the NYMEX, but according to Sterck, 275,000 ounces have already been moved since the start of the year.
“You can see that even to get to our number for 2025, you’d have to have quite a significant unwinding of those NYMEX exchange stock flows to get back to where our full year estimate is. So if we were to close the year today, the deficit would be more substantial than our current projection,” he said.
Trump policy, the auto industry and platinum
If US tariffs on Mexico and Canada do come into effect, platinum investors and the auto industry are likely to feel the pinch.
Sterck explained that, while the bulk of North American auto manufacturing is carried out in the United States, the auto sector is highly integrated. Mexico manufactures about 45 percent of the United States’ automobile parts and 15 percent of the country’s vehicles, and Canada supplies an additional 10 percent and 7.5 percent respectively.
These automobile parts include the catalytic converters, which have significant load-outs of the core platinum group metals (PGMs): platinum, palladium and rhodium.
According to Sterck, the overall fear is that the increased cost of new cars for US consumers caused by the tariffs will reduce demand, putting downward pressure on PGMs as well.
“In terms of platinum, the downside risk to platinum demand on our numbers in a worst-case scenario is about 97,000 ounces. For palladium, it’s more substantial, something in the order of 350,000 ounces,” he said.
While this may more significantly impact palladium markets, Sterck doesn’t see this potential hit to platinum demand shifting the platinum deficit that the WPIC is predicting for 2025.
Other policy decisions by the new US administration will likely provide support for platinum, however.
‘Sadly, it looks like the US is going to be rolling back on its environmental commitments,’ Sterck said. ‘Obviously, that could be positive in terms of petroleum demand for PGMs (and) internal combustion engine demand for PGMs.’
Additionally, slowing of demand growth for electric vehicles (EVs) adds potential tailwinds for automotive platinum demand. Sterck suggests several factors contribute to the slowing rates, including US policy and backlash against Tesla (NASDAQ:TSLA).
While some consumers are turning to battery electric vehicles from other automakers, he notes that the trend of slowing growth in EVs is leading more consumers to look to cars with internal combustion engines, both traditional and hybrid, which require PGMs in their catalytic converters.
Supply-side squeeze
On the supply side, Sterck sees consistent contraction in the mining supply.
“The reality is that there isn’t a (solely) platinum mine in the world,” he said.
‘These mines all produce — and therefore their economics depend upon — multiple different metals. They all produce all six of the PGMs, plus gold (and) nickel, copper and chrome.’
However, Sterck explained that lower prices for palladium, rhodium and more recently chrome has led some of the miners to restructure operations to focus on profitability rather than output. While this has been successful at supporting the mines’ economics, it has caused output to fall significantly.
He also says that the overall impact of the reduced output has been masked by platinum stockpiles entering the market, with higher inventory levels introduced in 2024.
He pointed to South Africa as an example, which saw reduced smelter output and a stockpiling of concentrate in 2022 and 2023 due to power shortages. In 2024, the decline in mine production came alongside an upside in refining those stockpiled materials, which boosted full-year numbers.
Platinum supply from recycling is expected to remain about 20 percent below the 10 year average at 1,496,000 ounces, a decrease of 278,000 ounces from the WPIC’s 2025 forecast in its November release. This drop was the largest difference between the two releases.
Sterck explained that one cause of depressed recycling supply in 2024 and 2025 is declining supplies of end-of-life vehicles.
“Part of that is related to COVID impacting supply chains, and then the semiconductor shortage reducing new vehicle production in the past and consumers being forced to run new vehicles for longer,” he said. However, he said there could be other reasons that aren’t as apparent.
What should investors know about platinum in 2025
As Sterck pointed out, the platinum market was volatile at the beginning of the year, so the 2025 WPIC forecast may need to be significantly adjusted. However, the group said the market will continue to experience structural deficits in 2025.
While investment demand surged 77 percent in 2024, Sterck sees a pullback of 14 percent in 2025, but even that is high compared to previous years.
“Overall, I think we’ve got 606,000 ounces projected in terms of total demand for 2025, a respectable level that’s historically elevated,” he said.
One significant area of growth so far in 2025 is futures trading on the NYMEX, with Sterck pointing to a 500 percent year-on-year increase in January.
However, there hasn’t been much price movement so far. Platinum has largely traded in the US$900 to US$1,100 per ounce range for the past year, but unusually, with the increased trading volume, the prices have narrowed.
“There’s increasing competition within the market for some sort of price direction, and at some point, the price has to break out of that narrowing range,” he said.
Given the market conditions for platinum, the WPIC expects that breakout would be a positive one, but it’s not a guarantee.
“When prices break out, it can go in both directions, so we will have to wait and see,’ Sterck said. ‘But it’s certainly very interesting, and there’s a limited amount of time left before something really needs to change.’
Securities Disclosure: I, Dean Belder, hold no direct investment interest in any company mentioned in this article.
This post appeared first on investingnews.com
Here’s a quick recap of the crypto landscape for Wednesday (March 12) as of 9:00 p.m. UTC.
Bitcoin and Ethereum price update
Bitcoin (BTC) is currently trading at US$83,016.38, reflecting a 0.2 percent decrease over the past 24 hours. The day’s trading range has seen a high of US$83,625.34 and a low of US$80,833.49.
Bitcoin has rebounded from its four-month low of US$76,600.
Despite a brief rise following a consumer price index report that pointed to cooling inflation, data analytics firm CryptoQuant warned of valuation metrics hinting at a further correction below US$70,000.
Ethereum (ETH) is priced at US$1,881.77, down 3.6 percent over the same period.
The cryptocurrency reached an intraday high of US$1912.08 and a low of US$1,841.97.
Glassnode indicated that Ethereum’s recent price drop near $1,900 led to the accumulation of a significant amount of ETH, which their cost-basis analysis suggests could act as a support level.
Altcoin price update
- Solana (SOL) is currently valued at US$125.10, down 2.4 percent over the past 24 hours. SOL rose to a high of US$128.44 and later fell to a low of US$123.40 on Wednesday.
- XRP is trading at US$2.24, reflecting a 1.6 percent increase over the past 24 hours. The cryptocurrency recorded an intraday high of US$2.24 and a low of US$2.14.
- Sui (SUI) is priced at US$2.22, down 2.4 percent over the past 24 hours. It achieved a daily high of US$2.31 and a low of US$2.19.
- Cardano (ADA) is trading at US$0.7299, reflecting a modest 0.1 percent increase over the past 24 hours. Its highest price on Wednesday was US$0.7541, with a low of US$0.7161.
Crypto news to know
BITCOIN’s second act
Senator Cynthia Lummis reintroduced the BITCOIN Act in US Congress on Tuesday (March 11), an initiative first introduced in July 2024, coinciding with then-presidential candidate Donald Trump’s promise to create a strategic Bitcoin reserve if he were elected.
Although the bill did not pass in the previous Congress, the updated version has garnered additional support from new co-sponsors, including Republican Senators Jim Justice, Tommy Tuberville, Roger Marshall, Marsha Blackburn and Bernie Moreno.
At a Bitcoin for America event hosted by the Bitcoin Policy Institute in Washington, DC, on Tuesday night, Rep. Nick Begich (R-AK) said he plans to introduce the bill to the House of Representatives.
The legislation would allow the United States Department of Treasury to hold approximately 5 percent of the total Bitcoin supply, “mirroring the size and scope of gold reserves held by the United States.” Additional Bitcoin could be purchased by “diversifying existing funds within the Federal Reserve System and Treasury Department.’
House votes to repeal IRS DeFi broker rule
On Tuesday, the US House of Representatives voted to repeal a rule that would have mandated decentralized finance (DeFi) protocols to report gross proceeds from crypto sales to the Internal Revenue Service (IRS), including information regarding taxpayers involved in the transactions.
The motion passed with a final tally of 292-132 in favor. This follows the US Senate’s March 4 vote on the motion to repeal, which passed with a 70-27 majority.
Republican Representative Mike Carey submitted the repeal motion alongside Senator Ted Cruz, arguing that the rule was invasive for taxpayers and would overwhelm the IRS, as well as stifle innovation in “an important new industry in the United States.
The White House has voiced support for the repeal. The motion will now need to pass a second Senate vote before passing President Donald Trump’s desk.
Franklin Templeton files to list spot XRP ETF
Franklin Templeton has joined eight other fund managers — Bitwise, ProSHares, 32Shares, Canary Capital, Wisdom Tree, CoinShares, Grayscale and Volatility Shares — seeking approval to list spot XRP exchange-traded funds (ETFs) from the US Securities and Exchange Commission (SEC). The fund manager applied on March 11.
On that same day, the SEC delayed decisions on numerous crypto-related filings, followed by two more delays on March 12. These included proposals for ETFs tracking Solana, DOGE, Litecoin, and XRP.
The Cboe BZX exchange has also filed two proposals to incorporate staking into Fidelity’s spot Ethereum exchange-traded fund (ETF) and the Franklin Ethereum ETF.
Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.
Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.
This post appeared first on investingnews.com
Red Metal Resources Ltd. (CSE: RMES) (OTC Pink: RMESF) (FSE: I660) (‘Red Metal’ or the ‘Company’) is pleased to announce it has now commenced an extensive sampling and mapping work program to follow-up on and extend previously identified veins that make up approximately 15km of veining extending along strike from the historic Carrizal Alto mine.
This active 2025 work program will continue work delineating the vast vein system on Carrizal property and aid in refining future drill targets. All samples will be sent for assay and the Company expects a steady stream of assay results shortly.
Figure 1: Brecciated vein from Level 7 of artisanal workings
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/4932/244415_dd829b6cf4c73861_001full.jpg
Red Metal Resources President and CEO, Caitlin Jeffs stated,‘We are now underway with our 2025 work program and are excited to build on our previous discoveries of up to 5.77% Copper. We believe we are in the top of a large IOCG system and that we are in the early stages of showing its full potential.’
Figure 2: Overview of Farellon Project, Carrizal, Chile
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/4932/244415_dd829b6cf4c73861_002full.jpg
(1)Management cautions that prospecting surface rock samples and associated assays, as discussed herein, are selective by nature and represent a point location, and therefore may not necessarily be fully representative of the mineralized horizon sampled.
A 2022 work program focused on mapping veins along strike of, and to the east of the main Farellon structure with the goal of developing new drill targets. New veins mapped and sampled include the Gorda vein which was drilled in Hole FAR-22-020. The Gorda vein lies 250 metres east of the Farellon structure which was mapped and sampled along strike for a full kilometre. A further five veins were identified and sampled in detail to develop 2025 and future drill targets throughout the property.
Highlights
- A high sample return of 5.77% Cu, 1.55% Co and 0.11 g/t Au two kilometres along strike to the north of the recent drilling on the Farellon structure
- Three veins mapped, each demonstrating over a kilometre of prospective strike length with mineralized grab samples
Table 1: Grab Sample Highlights (1)(2)
| Sample Number |
Northing UTM |
Easting UTM |
Elevation (asl) |
Weight of Sample (Kg) |
Au g/t | Co% | Cu% |
| 500818 | 6888943 | 309490 | 553 | 1.54 | 1.74 | 0.047 | 6.26 |
| 500902 | 6891077 | 310916 | 632 | 1.63 | 0.11 | 1.545 | 5.77 |
| 500832 | 6889540 | 311547 | 540 | 1.82 | 0.22 | 0.021 | 5.66 |
| 500895 | 6890377 | 310310 | 631 | 1.58 | 0.63 | 0.146 | 5.18 |
| 500887 | 6889724 | 311958 | 495 | 0.94 | 0.32 | 0.063 | 5.06 |
| 500803 | 6889197 | 309735 | 561 | 2.21 | 0.04 | 0.019 | 4.89 |
| 500822 | 6888323 | 309800 | 647 | 1.96 | 3.43 | 0.015 | 4.59 |
| 500830 | 6889441 | 311412 | 524 | 1.71 | 0.67 | 0.027 | 4.11 |
| 500827 | 6888543 | 310082 | 618 | 1.71 | 4.91 | 0.094 | 3.70 |
| 500894 | 6890373 | 310305 | 631 | 0.45 | 0.13 | 0.028 | 3.41 |
| 500844 | 6888968 | 310724 | 496 | 1.48 | 0.27 | 0.024 | 3.37 |
| 500854 | 6889477 | 310518 | 582 | 1.05 | 3.28 | 0.160 | 3.16 |
| 500837 | 6889267 | 311117 | 527 | 0.67 | 1.97 | 0.029 | 3.03 |
| 500814 | 6889114 | 309667 | 587 | 1.51 | 0.19 | 0.057 | 2.79 |
| 500858 | 6889836 | 310979 | 582 | 2.46 | 2.06 | 0.002 | 2.70 |
| 500834 | 6889309 | 312021 | 472 | 1.52 | 0.45 | 0.054 | 2.64 |
| 500824 | 6888423 | 309869 | 621 | 1.32 | 0.74 | 0.136 | 2.61 |
| 500833 | 6890107 | 311855 | 522 | 1.12 | 0.21 | 0.071 | 2.52 |
| 500820 | 6888717 | 309359 | 592 | 3.64 | 0.45 | 0.036 | 2.50 |
| 500831 | 6889472 | 311475 | 533 | 1.91 | 0.02 | 0.015 | 2.39 |
| 500859 | 6889807 | 310888 | 564 | 1.14 | 0.17 | 0.019 | 2.11 |
| 500840 | 6888767 | 310417 | 546 | 1.07 | 0.81 | 0.018 | 2.06 |
| 500850 | 6888284 | 310247 | 572 | 1.5 | 1.57 | 0.029 | 1.90 |
| 500816 | 6889020 | 309583 | 594 | 3.62 | 0.38 | 0.020 | 1.88 |
| 500868 | 6890705 | 311339 | 574 | 1.43 | 0.09 | 0.085 | 1.77 |
| 500886 | 6889679 | 312500 | 457 | 0.93 | 0.22 | 0.002 | 1.76 |
| 500806 | 6889420 | 309857 | 575 | 1.3 | 0.09 | 0.036 | 1.69 |
| 500819 | 6888717 | 309359 | 592 | 2.64 | 0.47 | 0.048 | 1.54 |
| 500855 | 6889630 | 310681 | 596 | 1.19 | 0.87 | 0.025 | 1.54 |
| 500852 | 6889527 | 310785 | 561 | 1.86 | 0.24 | 0.193 | 1.21 |
| 500829 | 6889352 | 311252 | 539 | 3.43 | 0.65 | 0.073 | 1.20 |
| 500856 | 6889748 | 310735 | 570 | 2.31 | 0.22 | 0.024 | 1.15 |
| 500835 | 6889244 | 311891 | 496 | 3.24 | 1.54 | 0.001 | 0.94 |
| 500838 | 6889227 | 311054 | 548 | 1.26 | 1.89 | 0.019 | 0.88 |
| 500892 | 6889011 | 312361 | 435 | 0.8 | 0.01 | 0.033 | 0.86 |
| 500826 | 6888696 | 310059 | 627 | 1.75 | 1.79 | 0.003 | 0.84 |
| 500801 | 6889269 | 309795 | 596 | 1.96 | 0.09 | 0.121 | 0.82 |
| 500823 | 6888344 | 309815 | 637 | 2.74 | 0.22 | 0.006 | 0.75 |
| 500853 | 6889444 | 310665 | 578 | 2.95 | 0.43 | 0.026 | 0.66 |
| 500802 | 6889233 | 309758 | 580 | 1.67 | 0.04 | 0.062 | 0.55 |
| 500825 | 6888485 | 309930 | 617 | 1.02 | 2.20 | 0.030 | 0.50 |
(1)Management cautions that prospecting surface rock samples and associated assays, as discussed herein, are selective by nature and represent a point location, and therefore may not necessarily be fully representative of the mineralized horizon sampled.
(2)This table represents a selection of highlights including 41 samples out of 102 samples taken
Qualified Person
The technical content of this news release has been reviewed and approved by Caitlin Jeffs, P. Geo, who is a Qualified Person (‘QP’) as defined in National Instrument 43-101, Standards of Disclosure for Mineral Projects.
About Red Metal Resources Ltd.
Red Metal Resources is a mineral exploration company focused on growth through acquiring, exploring and developing clean energy and strategic minerals projects. The Company’s portfolio of projects include seven separate mineral claim blocks and mineral claim applications, highly prospective for Hydrogen, covering 172 mineral claims and totaling over 4,546 hectares, located in Ville Marie, Quebec and Larder Lake, Ontario, Canada. As well, the Company has a Chilean copper project, located in the prolific Candelaria iron oxide copper-gold (IOCG) belt of Chile’s coastal Cordillera. Red Metal is quoted on the Canadian Securities Exchange under the symbol RMES, on OTC Link alternative trading system on the OTC Pink marketplace under the symbol RMESF and on the Frankfurt Stock Exchange under the symbol I660.
For more information, visit www.redmetalresources.com
Contact:
Red Metal Resources Ltd.
Caitlin Jeffs, President & CEO
1-866-907-5403
invest@redmetalresources.com
www.redmetalresources.com
Forward-Looking Statements – All statements in this press release, other than statements of historical fact, are ‘forward-looking information’ within the meaning of applicable securities laws. Red Metal provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to the ability to raise adequate financing, receipt of required approvals, as well as those risks and uncertainties identified and reported in Red Metal’s public filings under its SEDAR+ profile at www.sedarplus.ca. Although Red Metal has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results, and future events could differ materially from those anticipated in such statements. Red Metal disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.
Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/244415
News Provided by Newsfile via QuoteMedia
This post appeared first on investingnews.com
Quimbaya Gold Inc. (CSE: QIM) (OTCQB: QIMGF) (FSE: K05) (‘Quimbaya Gold’ or the ‘Company’) is pleased to announce that the Company has executed the final payment of 4 contract concessions totalling 1624 hectares in the Tahami project area. The company was able to amend the last payment terms of these concessions from $200,000 USD to $135,000 USD.
‘We are pleased that we were able to secure these important land packages with the final payments on our highly prospective Tahami area on amended terms that represented a 30% savings from the original last payments’, stated Alexandre P. Boivin, President and CEO.
The company also announces that it has extended the expiry date of an aggregate of 1,589,344 outstanding warrants of which 1,241,070 warrants were issued in connection with the closing of a non-brokered private placement on June 5, 2024 (the ‘June Warrants‘) and 348,274 warrants were issued in connection with the closing of a non-brokered private placement on November 1, 2024 (the ‘November Warrants‘).
The initial exercise price of the June Warrants and the November Warrants is $0.75 and remains unchanged. The June Warrants have an original expiration date of June 5, 2025 and the November Warrants have an original expiration date of November 1, 2025. The Company proposes to extend the expiration date of the June Warrants and November Warrants by one additional year to June 5, 2026 and November 1, 2026, respectively (the ‘Amendment’). All other terms and conditions of the June Warrants and the November Warrants will remain unchanged.
The Amendment is subject to final Canadian Securities Exchange (the ‘CSE‘) approval, as applicable. No action will be required on the part of the holders of the June Warrants and the November Warrants to give effect to the Amendment. In accordance with the requirements of the CSE, the terms of any warrants issued as compensation warrants or as finder warrants are not eligible for amendment.
528,570 of the June Warrants and 153,600 of the November Warrants are owned by insiders of the Company, representing 42.6% and 44.1%, respectively, of the aggregate number of warrants. As a portion of the June Warrants and the November Warrants are held by insiders of the Company, the Amendment may constitute a ‘related party transaction’ as defined under Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (‘MI 61-101‘). A material change report will be filed with respect to the Amendment as it pertains to insiders. The Amendment are exempt from the formal valuation and minority shareholder approval requirements under MI 61-101 as neither the fair market value of the June Warrants and the November Warrants issued to insiders nor the cash consideration paid for such June Warrants and November Warrants exceeds 25% of the market capitalization of the Company.
About Quimbaya Gold
Quimbaya is active in the exploration and acquisition of mining properties in the prolific mining districts of Colombia. Managed by an experienced team in the mining sector, Quimbaya is focused on three projects in the regions of Segovia (Tahami Project), Puerto Berrio (Berrio Project), and Abejorral (Maitamac Project), all located in Antioquia Department, Colombia.
Contact Information
Alexandre P. Boivin, President and CEO apboivin@quimbayagold.com
Jason Frame, Manager of Communications jason.frame@quimbayagold.com
Quimbaya Gold Inc.
Follow on X @quimbayagoldinc
Follow on LinkedIn @quimbayagold
Follow on Instagram @quimbayagoldinc
Follow on Facebook @quimbayagoldinc
Cautionary Statements
This news release contains forward-looking statements and/or forward-looking information (collectively, ‘forward-looking statements’) within the meaning of applicable securities laws. When used in this release, such words as ‘would’, ‘will’, ‘anticipates’, believes’, ‘estimates’, ‘potential’, ‘explores’ ‘expects’ and similar expressions, as they relate to the Company, or its management, are intended to identify such forward-looking statements. Such forward-looking statements reflect the current views of the Company with respect to future events, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the Company’s actual results, performance or achievements to be materially different from any expected future results, performance or achievement that may be expressed or implied by such forward-looking statements. Certain information and statements contained in this news release constitute forward-looking statements, which reflects the Company’s current expectations regarding future events, including but not limited: the initial depth of the Initial Drilling Campaign, if any; the successful completion of the Initial Drilling Campaign program and any future drilling under the initial contract, should they proceed, if at all; the ability of the Company to finance and execute its planned and future exploration activities; the quality of service and reputation of the Drilling Providers; the effectiveness of any potential drilling results in defining mineral resources or leading to a commercial discovery; the timing and process for the release of escrowed Consideration Units to the Drilling Providers; the anticipated cost of the Initial Drilling Campaign, if any, which may be subject to overruns; the receipt of regulatory approvals; the obligation for future updates as it relates to the Initial Drilling Campaign or future campaigns; and the initial and the overall success and advancement of the Company’s projects.
Forward-looking statements are subject to known and unknown risks, uncertainties and other important factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements, including but not limited to: the high degree of uncertainties inherent to feasibility and economic studies which are based to a significant extent on various assumptions; variations in commodity prices and exchange rate fluctuations; variations in cost of supplies and labour; lack of availability of qualified personnel; the quality of word provided by the Drilling Providers, if any; the receipt of necessary approvals; availability of financing; uncertainties and risks with respect to exploration and drilling; general business, economic, competitive, political and social uncertainties; certainty that finalized the commercial agreements will be successfully executed; risk of costs overruns with the Initial Drilling Campaign or future campaigns, if any, assurance that the final terms will align with those initially agreed upon or that the Initial Drilling Campaign will proceed as anticipated; timelines for drilling, if at all; obtaining required approvals of regulatory authorities; ability to access sufficient capital from internal and external sources; any assurances that the Company’s stock price will appreciate or maintain its current value; and the fact that the transaction will result in dilution to the Company’s existing shareholders, which may impact the market value of their holdings. The Company cautions that there is no guarantee that the planned Initial Drilling Campaign, if commenced, will yield successful results, identify mineral resources, or lead to further exploration or development. Exploration activities are inherently speculative, and drilling results may be inconclusive, insufficient, or unfeasible for further development. The cost estimates provided are subject to change, and the ability of the Company to continue exploration depends on factors such as market conditions, commodity prices, regulatory approvals, and access to additional funding. Additionally, the issuance of Consideration Units as compensation may remain subject to regulatory and exchange final approval, and there is no assurance that such approval will be obtained. The securities issued in connection with this transaction may be subject to resale restrictions under applicable securities laws and CSE policies. For a more fulsome additional list of risk factors please see the Company’s December 31, 2023, year-end Management Discussion and Analysis (‘MD&A’), 2024 third-quarter MD&A, available of SEDAR+ at www.sedarplus.ca.
Management of the Company has included the above summary of assumptions and risks related to forward-looking statements provided in this release in order to provide shareholders with a more complete perspective on the Company’s current and future operations and such information may not be appropriate for other purposes. The Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements included in this news release should not be read as guarantees of future performance or results. Accordingly, readers should not place undue reliance on forward-looking statements. The Company does not undertake to update any forward-looking statements, except in accordance with applicable securities laws.
This news release shall not constitute an offer to sell or the solicitation of an offer to buy the securities in any jurisdiction.
Neither CSE nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/244410
News Provided by Newsfile via QuoteMedia
This post appeared first on investingnews.com